Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Top Page
Intellia Therapeutics
(NASDAQ:NTLA)
54Neutral
Positive Factors
Clinical Trials
Enrollment for all three gene editing trials is tracking ahead of expectations, indicating strong progress in the company's research and development efforts.
Competitive Advantage
Enrollment in the U.S. for the MAGNITUDE study is progressing well despite the availability of newly approved treatments, suggesting a competitive edge for NTLA.
Financial Stability
Intellia Therapeutics has a strong cash position of $707 million, providing financial stability and runway into the first half of 2027.
Negative Factors
Capital Markets
Challenging capital markets and ongoing pipeline prioritization result in a reduction of the platform's tech value.
Market Competition
Brewing competition from Amvuttra (siRNA) and Attruby (pill) affects confidence in market position.
Regulatory Challenges
The price target has been adjusted to $10 from $14, based on regulatory headwinds in the gene therapy space after recent appointments at the FDA.
Intellia Therapeutics (NTLA) vs. S&P 500 (SPY)
Market Cap
$880.46M
Dividend YieldN/A
Average Volume (3M)3.39M
Price to Earnings (P/E)―
Beta (1Y)2.63
Revenue Growth-13.37%
EPS Growth2.57%
CountryUS
Employees403
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.10
Shares Outstanding103,583,400
10 Day Avg. Volume3,613,822
30 Day Avg. Volume3,389,257
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-2.37
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue4.32
Enterprise Value/Gross Profit17.17
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$32.81Price Target Upside286.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Intellia Therapeutics Business Overview & Revenue Model
Company DescriptionIntellia Therapeutics (NTLA) is a leading biotechnology company specializing in the development and commercialization of CRISPR/Cas9-based gene editing therapies. The company operates in the biotech sector with a focus on creating treatments that can potentially cure a wide range of genetic diseases by precisely editing disease-causing genes. Intellia's core products are its gene-editing platforms and therapies, which are in various stages of clinical development, targeting conditions such as transthyretin amyloidosis and hereditary angioedema.
How the Company Makes MoneyIntellia Therapeutics makes money primarily through strategic collaborations, partnerships, and licensing agreements with other pharmaceutical and biotech companies. These partnerships often provide milestone payments and royalties based on the successful development and commercialization of therapies using Intellia's proprietary CRISPR/Cas9 technology. Additionally, Intellia may generate revenue from government grants and research funding to support their innovative projects. As their therapies progress through clinical trials and potentially reach the market, product sales will become a significant revenue stream for the company.
Intellia Therapeutics Financial Statement Overview
Summary
Intellia Therapeutics is in a typical growth and development phase for a biotech company, characterized by high R&D expenses leading to net losses and negative cash flows. While the company maintains a strong cash position, its revenue has dwindled, and its balance sheet reflects declining shareholder equity. The financials suggest the firm is investing heavily in its pipeline, which is common in biotechnology, but it faces significant risks related to its future revenue generation and profitability.Income Statement
Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.15
Very Negative
Balance Sheet
The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.40
Negative
Cash Flow
The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 57.88M | 36.27M | 52.12M | 33.05M | 57.99M | Gross Profit |
| 47.59M | 27.30M | 44.55M | 26.16M | -92.41M | EBIT |
| -534.26M | -515.29M | -458.16M | -267.85M | -136.58M | EBITDA |
| -508.74M | -506.31M | -450.59M | -260.96M | -130.27M | Net Income Common Stockholders |
| -519.02M | -481.19M | -490.21M | -259.72M | -125.57M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 601.51M | 912.22M | 1.26B | 1.09B | 597.37M | Total Assets |
| 1.19B | 1.30B | 1.52B | 1.29B | 676.32M | Total Debt |
| 210.20M | 115.35M | 130.70M | 74.02M | 39.30M | Net Debt |
| 21.02M | -111.40M | -392.80M | -49.38M | -120.72M | Total Liabilities |
| 319.06M | 250.81M | 284.53M | 254.22M | 149.25M | Stockholders Equity |
| 871.96M | 1.05B | 1.24B | 1.04B | 527.07M |
| Cash Flow | Free Cash Flow | |||
| -354.66M | -408.07M | -391.68M | -237.79M | -53.50M | Operating Cash Flow |
| -348.88M | -394.09M | -333.29M | -225.03M | -49.91M | Investing Cash Flow |
| 125.57M | -31.35M | 160.31M | -550.78M | -214.49M | Financing Cash Flow |
| 185.75M | 130.32M | 582.96M | 736.69M | 371.78M |
Intellia Therapeutics Technical Analysis
Positive
8.50
Price Trends
8.16
Positive
9.45
Negative
14.06
Negative
Market Momentum
0.04
Negative
53.63
Neutral
53.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Positive. The current price of 8.5 is above the 20-day moving average (MA) of 8.23, above the 50-day MA of 8.16, and below the 200-day MA of 14.06, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 53.63 is Neutral, neither overbought nor oversold. The STOCH value of 53.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTLA.
Intellia Therapeutics Risk Analysis
Intellia Therapeutics disclosed 66 risk factors in its most recent earnings report. Intellia Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intellia Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $880.46M | ― | -57.92% | ― | -13.37% | 2.57% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
48 Neutral | $473.71M | ― | -35.41% | ― | -39.92% | 7.38% | |
47 Neutral | $573.64M | ― | -33.48% | ― | -25.88% | -29.16% | |
47 Neutral | $728.81M | ― | -64.16% | ― | -30.25% | -5.92% | |
44 Neutral | $635.89M | ― | -44.59% | ― | -73.79% | -5.24% | |
40 Underperform | $700.30M | ― | -60.45% | ― | ― | 6.99% |
* Healthcare Sector Average
Performance Comparison
NTLA
Intellia Therapeutics
8.50
-17.39
-67.17%
XNCR
Xencor
8.06
-15.69
-66.06%
RCKT
Rocket Pharmaceuticals
6.50
-16.33
-71.53%
ARVN
Arvinas Holding Company
6.49
-26.77
-80.49%
VIR
Vir Biotechnology
4.60
-5.09
-52.53%
NRIX
Nurix Therapeutics
9.56
-6.63
-40.95%
Intellia Therapeutics Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 16.60%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Positive
Intellia Therapeutics showed strong progress in its clinical pipeline with advancements in Phase 3 studies and key regulatory milestones. Financially, the company maintains a robust position despite some short-term revenue declines and restructuring costs, which are expected to bring future savings. The overall sentiment is positive, driven by significant clinical and regulatory advancements outweighing the financial challenges.Q1-2025 Updates
Positive Updates
Progress in Phase 3 Studies
Intellia dosed the first patient in their Phase 3 study for hereditary angioedema (HAE) and for hereditary ATTR with polyneuropathy. Enrollment in the global Phase 3 HAELO study for HAE is progressing ahead of schedule, and the Phase 3 MAGNITUDE study for ATTR with cardiomyopathy is also ahead of schedule with over 90 sites actively enrolling.
Regulatory Milestones
The FDA granted Intellia the RMAT designation for nexiguran ziclumeran (nex-z) for the treatment of ATTR with cardiomyopathy, adding to prior RMAT designations for ATTR with polyneuropathy and NTLA-2002 in HAE.
Strong Financial Position
Intellia maintains a solid balance sheet with cash, cash equivalents, and marketable securities totaling approximately $707.1 million as of March 31, 2025. The company expects a year-over-year decline in GAAP operating expenses of between 5% and 10% and has sufficient funds to operate into the first half of 2027.
Positive Clinical Data
Upcoming data presentations include two-year follow-up data from NTLA-2002 at the European Academy of Allergy and Clinical Immunology Congress and longer-term data from the Phase 1 study for ATTR amyloidosis, extending the durability window out to at least three years.
Negative Updates
Decrease in Collaboration Revenue
Collaboration revenue decreased to $16.6 million during the first quarter of 2025 compared to $28.9 million during the first quarter of 2024, primarily driven by a decrease under the AvenCell License and Collaboration Agreement.
Employee and Real Estate Costs
Intellia incurred non-recurring costs related to decisions to prioritize the portfolio and reduce the real estate footprint and workforce, which affected short-term financials despite long-term cost savings.
Company Guidance
In the first quarter of 2025, Intellia achieved significant milestones, including dosing the first patients in Phase 3 studies for hereditary angioedema (HAE) and ATTR amyloidosis with polyneuropathy. Enrollment in the global Phase 3 HAELO study is progressing rapidly, with completion expected by the end of the third quarter. The Phase 3 MAGNITUDE study for ATTR with cardiomyopathy is also ahead of schedule, with over 90 active sites and cumulative enrollment expected to exceed 550 patients by year-end. Financially, Intellia reported cash, cash equivalents, and marketable securities of approximately $707.1 million as of March 31, 2025, down from $861.7 million at the end of 2024. The company maintains a strong balance sheet, with a quarterly cash use estimate of $95 million for 2025 and 2026, and expects its current cash to fund operations into the first half of 2027. Revenue for Q1 2025 was $16.6 million, with R&D expenses of $108.4 million and G&A expenses of $29 million. The company is on track to file its first BLA in 2026, with a focus on bringing one-time therapies to market efficiently.Intellia Therapeutics Corporate Events
Product-Related Announcements
Intellia Therapeutics Reports Positive Phase 1 Trial Results
Positive
May 19, 2025
On May 18, 2025, Intellia Therapeutics announced positive two-year follow-up data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The study showed a significant reduction in serum TTR levels and clinically meaningful improvements in neuropathic impairment measures, with no serious adverse events, indicating potential for nex-z as a one-time treatment. The results were presented at the Peripheral Nerve Society Annual Meeting, highlighting the drug’s potential to improve outcomes for patients who previously showed disease progression on patisiran.
The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.
Spark’s Take on NTLA Stock
According to Spark, TipRanks’ AI Analyst, NTLA is a Neutral.
The overall stock score for Intellia Therapeutics reflects a mixed yet promising outlook. The company’s strong clinical progress and regulatory milestones provide a positive sentiment, enhancing its future potential. However, current financial challenges, including declining revenues and net losses, weigh heavily on the score. The technical analysis indicates short-term momentum, but long-term trends suggest caution. The valuation remains challenging due to negative earnings, typical in the biotech sector.
To see Spark’s full report on NTLA stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.